DBV Technologies (NASDAQ:DBVT) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS

DBV Technologies (NASDAQ:DBVT) posted its quarterly earnings results on Thursday. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.10, Zacks reports. The company had revenue of $8.88 million for the quarter, compared to analyst estimates of $1.10 million. During the same quarter in the prior year, the business posted ($0.23) earnings per share.

DBV Technologies Trading Up 0.5 %

NASDAQ DBVT traded up $0.00 on Friday, hitting $0.83. 75,461 shares of the company were exchanged, compared to its average volume of 50,485. The firm has a 50 day moving average of $0.87 and a two-hundred day moving average of $1.04. The company has a market cap of $160.05 million, a P/E ratio of -1.48 and a beta of 0.76. DBV Technologies has a 1-year low of $0.65 and a 1-year high of $2.37.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Commonwealth Equity Services LLC acquired a new position in DBV Technologies during the 3rd quarter valued at about $26,000. Two Sigma Investments LP lifted its position in DBV Technologies by 80.9% during the 3rd quarter. Two Sigma Investments LP now owns 35,920 shares of the company’s stock valued at $64,000 after purchasing an additional 16,066 shares during the period. Envestnet Asset Management Inc. lifted its position in DBV Technologies by 43.3% during the 4th quarter. Envestnet Asset Management Inc. now owns 54,497 shares of the company’s stock valued at $83,000 after purchasing an additional 16,469 shares during the period. BNP Paribas Arbitrage SNC lifted its position in DBV Technologies by 74.2% during the 2nd quarter. BNP Paribas Arbitrage SNC now owns 39,034 shares of the company’s stock valued at $74,000 after purchasing an additional 16,626 shares during the period. Finally, BNP Paribas Arbitrage SA acquired a new position in DBV Technologies during the 2nd quarter valued at about $49,000. 23.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of DBV Technologies in a research note on Wednesday, February 21st. StockNews.com assumed coverage on shares of DBV Technologies in a research note on Sunday, March 3rd. They issued a “hold” rating for the company.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis.